ClinicalTrials.gg
Active, not recruitingNCT03821935Updated May 25, 2025

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of Livmoniplimab and Budigalimab in Advanced Solid Tumors Cancer, sponsored by AbbVie. Active, not recruiting at 64 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-25.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
364
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study will determine the recommended Phase 2 dose (RP2D) of livmoniplimab (ABBV-151) administered as monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of livmoniplimab alone and in combination with budigalimab. The study will consist of 2 parts: dose escalation and dose expansion.

02

Conditions studied

  • Advanced Solid Tumors Cancer

Keywords

  • Advanced Solid Tumors Cancer
  • cancer
  • Solid Tumors
  • metastatic
  • monotherapy
  • combination therapy
  • triple negative breast cancer (TNBC)
  • pancreatic adenocarcinoma
  • urothelial cancer
  • hepatocellular carcinoma (HCC)
  • head and neck squamous cell carcinoma (HNSCC)
  • Colorectal cancer
  • Ovarian granulosa cell tumors
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 364 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.

Of its 360 completed or terminated interventional studies of FDA-regulated products, 216 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For Dose Escalation only: Participants with an advanced solid tumor who are considered to or intolerant of all existing therapy(ies) known to provide a clinical benefit for their condition. Additionally, participants who have been offered standard therapies and refused, or who are considered ineligible for standard therapies, may be eligible for this study on a case-by-case basis, after discussion with and agreement from the sponsor. Participants with pancreatic adenocarcinoma, urothelial cancer (UC), hepatocellular carcinoma (HCC), or head and neck squamous cell carcinoma (HNSCC) who are being considered for the dose escalation cohorts must also meet the histology specific eligibility criteria described below for dose expansion.
  • For Dose Expansion only participants must meet criteria specific to the type of cancer:

    • Pancreatic adenocarcinoma and have disease progression during or after 1 systemic therapy (gemcitabine monotherapy or in combination with other agents, FOLFIRINOX [or another regimen including both 5-fluorouracil and oxaliplatin], capecitabine monotherapy or in combination with other agents) administered in the adjuvant, locally advanced, or setting. If the therapy was used in an setting, disease progression must have occurred within 6 months of completing adjuvant therapy.
    • UC of the bladder and urinary tract and must have progressed following treatment with:
    • Cohort 4: A platinum-based regimen (administered in any ) and a programmed death 1/programmed death ligand 1 (PD1/PDL1) antagonist administered in the recurrent or metastatic setting (progression following a PD1/PDL1 antagonist is defined as unequivocal progression on or within 3 months of the last dose of anti-PD1 or anti-PDL1 therapy).
    • Cohort 11: One or more prior line of therapy in the locally advanced or metastatic setting. Participant must have experienced radiographic progression or relapse during or after a CPI (anti-PD1 or ) for locally advanced or metastatic disease.
    • HCC and must have disease progression during or after 1 prior line of systemic therapy.
    • HNSCC (arising from the oral cavity, oropharynx, hypopharynx, or larynx) and must have progressed following treatment with platinum-based regimen (administered in any line of therapy) and a PD1/PDL1 antagonist administered in the recurrent or metastatic setting (progression following a PD1/PDL1 antagonist is defined as unequivocal progression on or within 3 months of the last dose of anti-PD1 or anti-PDL1 therapy).
    • Microsatellite stable colorectal cancer (MSS-CRC) [unselected] participants with microsatellite stable or mismatch repair proficient colorectal adenocarcinoma (as determined by polymerase chain reaction (PCR)/Next-Generation sequencing (NGS) or immunohistochemistry (IHC), respectively) who have received 1-2 prior chemotherapy regimens.
    • Non-small cell lung cancer (NSCLC) relapsed/refractory (R/R): Participants with or cytologically confirmed advanced or metastatic NSCLC who have received 1 prior line of chemotherapy and 1 prior anti-PD-(L)1 antibody, administered either concurrently or sequentially in the metastatic setting.
    • MSS-CRC (CMS4 enriched): Participants with microsatellite stable or mismatch repair proficient colorectal adenocarcinoma who have received prior fluorouracil-based combination chemotherapy regimens including oxaliplatin and irinotecan (with or without VEGF and/or EGFR targeted agents) and with a CMS4 subtype as determined by NGS of tumor . Archival tissue must be submitted for assessment of CMS4 subtype status during prescreening. Participants must have progressed on or refused available standard of care therapies. Additionally, participant who are considered not appropriate or ineligible for available standard of care therapies per investigator assessment will be eligible for this study.
    • Ovarian granulosa (OG) cell tumor: Participants with histologically confirmed advanced nonresectable or metastatic adult granulosa cell tumor of the ovary that is not amenable to curative intent surgery or radiation. Additionally, there is documentation of radiological evidence of relapse after at least 1 line of systemic chemotherapy.
  • Participant has an (ECOG) Performance Status of 0 to 1.
  • Participant has adequate bone marrow, renal, hepatic, and coagulation function.
  • Must have a viral status consistent with the requirements described in the protocol specific to type of cancer and stage of study (Dose Escalation or Dose Expansion).

Exclusion criteria

Exclusion Criteria:

  • For Dose Expansion only:

    • Participants with HCC, pancreatic adenocarcinoma, or MSS-CRC having prior exposure to a prior /PD-L1 antagonist in any .
    • Participants (except for participants with urothelial cancer or HNSCC) who have had prior exposure to immunotherapies as listed in the protocol.
  • Has received anticancer therapy including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any therapy within a period of 5 half-lives or 28 days (whichever is shorter), prior to the first dose of the study drug.
  • Participant has unresolved AEs > Grade 1 from prior anticancer therapy except for alopecia.
  • Has a history of primary immunodeficiency, bone marrow transplantation, solid organ transplantation, or previous clinical diagnosis of tuberculosis.
  • Has a known uncontrolled to the central nervous system (with certain exceptions).
  • Current or prior use of medication within 14 days prior to the first dose of the study drug.
  • Has uncontrolled condition(s).
  • History of inflammatory bowel disease, interstitial lung disease or pneumonitis, myocarditis, Stevens-Johnson syndrome, toxic epidermal necrolysis or drug reaction with eosinophilia and systemic symptoms (DRESS).
  • administration \<= 28 days prior to the first dose of study drug.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
364 participants (actual)

Study arms

  • Experimental
    Dose Escalation: Cohort 1 Livmoniplimab

    Various doses of Livmoniplimab administered during dose escalation to determine the Recommended Phase 2 Dose (RP2D).

    Drug: Livmoniplimab

  • Experimental
    Dose Escalation: Cohort 2 Livmoniplimab + Budigalimab

    Various doses of Livmoniplimab + Budigalimab administered during dose escalation to determine the Recommended Phase 2 Dose (RP2D).

    Drug: Livmoniplimab · Drug: Budigalimab

  • Experimental
    Dose Expansion: Cohort 3 Livmoniplimab + Budigalimab

    Participants with programmed cell death protein 1 (PD-1)-naïve pancreatic adenocarcinoma will receive livmoniplimab at the RP2D Q2W plus budigalimab Dose A administered Q4W.

    Drug: Livmoniplimab · Drug: Budigalimab

  • Experimental
    Dose Expansion: Cohort 4 Livmoniplimab + Budigalimab

    Participants with PD-1-ref urothelial cancer will receive livmoniplimab at the RP2D Q2W plus budigalimab Dose A administered Q4W.

    Drug: Livmoniplimab · Drug: Budigalimab

  • Experimental
    Dose Expansion: Cohort 5 Livmoniplimab + Budigalimab

    Participants with PD-1-naïve hepatocellular carcinoma (HCC) will receive livmoniplimab at the RP2D Q2W plus budigalimab Dose A administered Q4W.

    Drug: Livmoniplimab · Drug: Budigalimab

  • Experimental
    Dose Expansion: Cohort 6 Livmoniplimab + Budigalimab

    Participants with PD-1-ref head and neck squamous cell carcinoma (HNSCC) will receive livmoniplimab at the RP2D Q2W plus budigalimab Dose A administered Q4W.

    Drug: Livmoniplimab · Drug: Budigalimab

  • Experimental
    Dose Expansion: Cohort 7 Livmoniplimab + Budigalimab

    Participants with PD-1-naïve microsatellite stable colorectal cancer (MSS-CRC) \[unselected\] will receive livmoniplimab at the RP2D Q2W plus budigalimab Dose A administered Q4W.

    Drug: Livmoniplimab · Drug: Budigalimab

  • Experimental
    Dose Expansion: Cohort 8 Livmoniplimab + Budigalimab

    Participants with non-small cell lung cancer (NSCLC) \[programmed death ligand 1 (PDL1) relapsed/refractory (R/R)\] will receive livmoniplimab at the RP2D Q2W plus budigalimab Dose A administered Q4W.

    Drug: Livmoniplimab · Drug: Budigalimab

  • Experimental
    Dose Expansion: Cohort 10A Livmoniplimab + Budigalimab

    Participants with microsatellite stable colorectal cancer (MSS-CRC) \[consensus molecular subtype 4 (CMS4) enriched\] will receive livmoniplimab at the dose B Q3W plus budigalimab Dose B administered Q3W.

    Drug: Livmoniplimab · Drug: Budigalimab

  • Experimental
    Dose Expansion: Cohort 10B Livmoniplimab + Budigalimab

    Participants with MSS-CRC (CMS4 enriched) will receive livmoniplimab at the dose C Q3W plus budigalimab Dose B administered Q3W.

    Drug: Livmoniplimab · Drug: Budigalimab

  • Experimental
    Dose Expansion: Cohort 11A Livmoniplimab + Budigalimab

    Participants with PD-1-ref urothelial cancer will receive livmoniplimab at the Dose B Q3W plus budigalimab Dose B administered Q3W.

    Drug: Livmoniplimab · Drug: Budigalimab

  • Experimental
    Dose Expansion: Cohort 11B Livmoniplimab + Budigalimab

    Participants with PD-1-ref urothelial cancer will receive livmoniplimab at the Dose C Q3W plus budigalimab Dose B administered Q3W.

    Drug: Livmoniplimab · Drug: Budigalimab

  • Experimental
    Dose Expansion: Cohort 11C Budigalimab

    Participants with PD-1-ref urothelial cancer will receive budigalimab Dose B administered Q3W.

    Drug: Budigalimab

  • Experimental
    Dose Expansion: Cohort 12A Livmoniplimab + Budigalimab

    Participants with PD-1-naïve ovarian granulosa (OG) cell tumors will receive livmoniplimab at the Dose B Q3W plus budigalimab Dose B administered Q3W.

    Drug: Livmoniplimab · Drug: Budigalimab

  • Experimental
    Dose Expansion: Cohort 12B Livmoniplimab + Budigalimab

    Participants with PD-1-naïve ovarian granulosa (OG) cell tumors will receive livmoniplimab at the Dose C Q3W plus budigalimab Dose B administered Q3W.

    Drug: Livmoniplimab · Drug: Budigalimab

Interventions

  • Liquid for intravenous infusion.

    Also known as: ABBV-151

  • Lyophilized powder for solution for intravenous infusion.

    Also known as: ABBV-181

06

What researchers measure

Primary outcomes

  1. Dose Escalation: Recommended Phase 2 Dose (RP2D) Livmoniplimab Monotherapy

    The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for the dose expansion arms, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation portion of the study.

    Time frame: Up to 28 days after the first dose of Livmoniplimab monotherapy

  2. Dose Escalation: RP2D Livmoniplimab + Budigalimab Combination Therapy

    The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for the dose expansion arms, based on safety, tolerability, efficacy, pharmacokinetics (PK), and pharmacodynamic (PD) data collected during the dose escalation portion of the study.

    Time frame: Up to 28 days after the first dose of Livmoniplimab and Budigalimab combination therapy

  3. Dose Expansion: Objective Response Rate (ORR)

    ORR defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: Up to approximately 6 months after the first dose date of last participant in Dose Expansion

Secondary outcomes

  1. Dose Expansion: Duration of Response (DOR)

    The DOR for a responder is defined as the time from the participant's initial objective response to the first date of either disease progression or death, whichever occurs first.

    Time frame: Up to approximately 6 months after the first dose date of last participant in Dose Expansion

  2. Dose Expansion: Progression-free Survival (PFS)

    Progression-free survival is defined as the time from the participant's first dose of study treatment (livmoniplimab or budigalimab) to the first date of either disease progression or death, whichever occurs first.

    Time frame: Up to approximately 6 months after the first dose date of last participant in Dose Expansion

  3. Maximum Observed Serum Concentration (Cmax) of Livmoniplimab

    Maximum Serum Concentration (Cmax) of livmoniplimab.

    Time frame: Up to approximately 70 days after initial dose of study drug

  4. Time to Maximum Observed Serum Concentration (Tmax) of Livmoniplimab

    Time to maximum serum concentration (Tmax) of livmoniplimab.

    Time frame: Up to approximately 70 days after initial dose of study drug

  5. Area Under the Plasma Concentration-time Curve over time from 0 to last measurable concentration (AUCτ) of Livmoniplimab

    Area under the serum concentration-time curve from time 0 to the time of the last measurable concentration (AUCτ) of livmoniplimab.

    Time frame: Up to approximately 70 days after initial dose of study drug

  6. Terminal-phase Elimination Rate Constant (β) of Livmoniplimab

    Apparent terminal phase elimination rate constant (β or Beta) of livmoniplimab.

    Time frame: Up to approximately 70 days after initial dose of study drug

  7. Terminal Phase Elimination Half-life (t1/2) of Livmoniplimab

    Terminal phase elimination half-life (t1/2) of livmoniplimab.

    Time frame: Up to approximately 70 days after initial dose of study drug

  8. Maximum Observed Serum Concentration (Cmax) of Budigalimab

    Maximum Serum Concentration (Cmax) of budigalimab.

    Time frame: Up to approximately 70 days after initial dose of study drug

  9. Time to Maximum Observed Serum Concentration (Tmax) of Budigalimab

    Time to maximum serum concentration (Tmax) of budigalimab.

    Time frame: Up to approximately 70 days after initial dose of study drug

  10. Area Under the Plasma Concentration-time Curve over time from 0 to last measurable concentration (AUCτ) of Budigalimab

    Area under the serum concentration-time curve from time 0 to the time of the last measurable concentration (AUCτ) of budigalimab.

    Time frame: Up to approximately 70 days after initial dose of study drug

  11. Terminal-phase Elimination Rate Constant (β) of Budigalimab

    Apparent terminal phase elimination rate constant (β or Beta) of budigalimab.

    Time frame: Up to approximately 70 days after initial dose of study drug

  12. Terminal Phase Elimination Half-life (t1/2) of Budigalimab

    Terminal phase elimination half-life (t1/2) of budigalimab.

    Time frame: Up to approximately 70 days after initial dose of study drug

  13. Number of Participants With Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.

    Time frame: Up to approximately 9 months after the first dose date of last participant

  14. Change in Vital Signs

    Number of participants with clinically significant change from baseline in vital signs like systolic and diastolic blood pressure will be reported.

    Time frame: Up to approximately 6 months after the first dose date of last participant

  15. Change in Laboratory Parameters

    Number of participants with clinically significant change from baseline in clinical laboratory test results like hematology will be reported.

    Time frame: Up to approximately 6 months after the first dose date of last participant

  16. Change in Electrocardiogram (ECG)

    12-lead resting ECGs will be recorded. Parameters include RR interval, PR interval, QT interval, and QRS duration.

    Time frame: Up to approximately 6 months after the first dose date of last participant

  17. Incidence of Anti-drug Antibody (ADA)

    The number of participants with anti-drug antibodies.

    Time frame: Up to approximately 6 months after the first dose date of last participant

  18. Dose Expansion Cohorts 10 to 12: Overall Survival (OS)

    OS is defined as time from first study treatment to death due to any cause.

    Time frame: Up to approximately 6 months after the first dose date of last participant in Cohorts 10 to 12

07

Study locations

64 sites
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2019 (actual). Primary completion is estimated for Jun 2027, 100 months after the start.

Of 676 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's planned 100 months is above that.

Counting every sponsor, half of 903 studies reached it within 40 months; a quarter within 23 and three quarters within 64.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2019
First posted
Jan 30, 2019
StartActual
Feb 21, 2019
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
May 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03821935
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jan 30, 2019
Start date
Feb 21, 2019
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
May 25, 2025

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Livmoniplimab · Budigalimab

Start the discussion